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ABSTRACT
Purpose Tobramycin is an aminoglycoside antibiotic of
which the 24 h exposure correlates with efficacy. Recently,
we found that clearance of the aminoglycoside gentamicin
correlates with total body weight (TBW). In this study, we
investigate the full pharmacokinetic profile of tobramycin in
obese and non-obese individuals with normal renal function.
Methods Morbidly obese individuals (n = 20) undergoing
bariatric surgery and non-obese healthy volunteers (n= 8),
with TBW ranging 57–194 kg, received an IV dose of
tobramycin with plasma concentrations measured over 24 h
(n= 10 per individual). Statistical analysis, modelling and sim-
ulations were performed using NONMEM.
Results In a two-compartment model, TBW was the best pre-
dictor for central volume of distribution (p<0.001). For clearance,
MDRD (de-indexed for body surface area) was identified as best
covariate (p< 0.001), and was superior over TBW ((p<0.05).
Other renal function estimates (24 h urine GFR and de-indexed
CKD-EPI) led to similar results as MDRD (all p<0.001)).
Conclusions In obese and non-obese individuals with normal
renal function, renal function estimates such as MDRD were
identified as best predictors for tobramycin clearance, which
may imply that other processes are involved in clearance of
tobramycin versus gentamicin. To ensure similar exposure
across body weights, we propose a MDRD-based dosing no-
mogram for obese patients.
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ABBREVIATIONS
(pvc)VPC (prediction-variability corrected)
Visual Predictive Check
ABW Adjusted Body Weight
AUC Area Under the Curve
AUC24 24 h Area Under the Curve
BMI Body Mass Index
BSA Body Surface Area
CG Cockcroft Gault
CKD-EPI Chronic Kidney Disease
Epidemiology Collaboration
GFR Glomerular Filtration Rate
GOF Goodness-of-fit
IBW Ideal Body Weight
IIV Inter-individual variability
LBW Lean Body Weight
MDRD Modification of Diet in Renal Disease
MIC Minimal Inhibitory Concentration
OFV Objective Function Value
TBW Total Body Weight
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INTRODUCTION
The global prevalence of obesity and morbid obesity,
which is commonly defined as a body mass index (BMI)
over 30 and 40 kg/m2, respectively, is rapidly rising. In
2015, over 600 million adults were obese worldwide, ac-
counting for 12% of the entire adult population (1). Due
to physiological changes associated with obesity, such as
an increase in fat and other tissue, differences in liver size,
liver flow, liver enzyme activity and glomerular filtration
rate (GFR), obesity-related changes in pharmacokinetic
(PK) and/or pharmacodynamic (PD) parameters of drugs
may be expected (2). However, the exact quantification of
these changes in PK and PD is lacking for many drugs.
This is of particular relevance for drugs for which a target
concentration and/or exposure related to efficacy or safe-
ty has been identified, like in the case of aminoglycosides.
These antibiotics, such as gentamicin and tobramycin, are
used for the treatment of severe infections, with their ef-
ficacy being closely related to a (timely) attainment of an
adequate plasma exposure (depicted by the 24-h area un-
der the curve (AUC24) over the minimal inhibitory con-
centration (MIC) of the microbiological target (3–5). Since
in the general population AUC24 closely correlates with
the maximum plasma concentration (Cmax) and measure-
ment of an AUC puts substantial burden to the treated
patient, the Cmax is often used as measure of efficacy with
target values between 15 and 20 mg/L. Despite this ap-
proach that is used in clinical practice, the AUC24 is still
considered the cornerstone PD-index for aminoglycoside
effectivity and toxicity (5–7), with 75 mg*h/L being pro-
posed as a pharmacodynamic target with an optimal ef-
fect and acceptable risk for toxicity (5). However, this is
based on the assumption that MICs are not higher than
1 mg/L, whereas the wild-type population of most gram-
negatives extend to 2 mg/L (5,8).
To date, in clinical practice tobramycin is dosed on a
mg/kg basis. Clinicians may however be reluctant to use
mg/kg dosing in (morbidly) obese patients, since high
trough levels (i.e. >1 mg/L 24 h after dosing) are associ-
ated with side effects such as nephro- or ototoxicity (9,10).
Therefore, over the past decades, several alternative body
size descriptors to guide aminoglycoside dosing have been
proposed, such as adjusted body weight (ABW) and lean
body weight (LBW) (11–16). These dosing measures were
mainly proposed to compensate for a body weight-related
increase in volume of distribution (Vd) which was found in
these studies (11–16), with Vd being the parameter that
determines Cmax. However, since not Vd, but drug clear-
ance drives the AUC, it is essential to clarify what body
size descriptor or parameter best predicts clearance with
increasing body weight. For the aminoglycoside gentami-
cin, we recently found that in obese individuals, TBW was
the most predictive descriptor for clearance, albeit in a
nonlinear manner (17). In the current prospective rich
sampling study, we investigate the pharmacokinetics of
tobramycin in morbidly obese and non-obese individuals
with normal renal function (eGFR>60 ml/min), in order
to investigate how tobramycin clearance and other PK
parameters change in obesity. In line with our previous
study on gentamicin PK in the obese, beside weight mea-
sures, other measures like renal function estimates were
investigated as covariates. The results are used to guide
dosing of tobramycin in (morbidly) obese individuals.
MATERIALS AND METHODS
This prospective observational study was registered in the
Dutch Trial Registry (NTR6058), approved by the local hu-
man research and ethics committee and was conducted in
accordance with the principles of the Declaration of Helsinki.
Participants
Morbidly obese patients (BMI > 40 kg/m2 or > 35 kg/m2
with comorbidities) scheduled for bariatric surgery (laparo-
scopic gastric sleeve or gastric bypass) were considered for
inclusion. In addition, a group of non-obese healthy volun-
teers (body mass index (BMI) 18–25 kg/m2) was included.
Participants were excluded when they had a known allergy
to aminoglycosides, used potentially nephrotoxic medication
in the week before surgery (such as lisdiuretics, vancomycin,
ACE-inhibitors, non-steroid anti-inflammatory drugs), had a
known renal insufficiency (eGFR <60 ml/min, using the
Modification of Diet in Renal Disease (MDRD) (non-obese)
or LBW in the Cockcroft Gault formula (obese) (18)), were
pregnant or breastfeeding. Before inclusion, all participants
provided written informed consent.
Study Procedures
Twenty morbidly obese patients received 5 mg/kg LBW (cal-
culated according to Janmahasatian (19)) tobramycin on the
day of surgery as a single dose infused over 0.5 h, after which
venous blood samples were collected at t = 5 min after end of
infusion, followed by collections at t = 1, 1.5, 2, 2.5, 3.5, 4.5, 6,
12 and 24 h after start of infusion. 3 mL blood samples were
collected in lithium-heparin tubes, centrifuged at 1900 g for
5 min, and plasma was stored at −80°C until analysis. Eight
non-obese healthy volunteers received a single dose of
5 mg/kg TBW tobramycin, infused over 0.5 h, after which
the same sampling scheme was employed.
In order to measure the glomerular filtration rate (GFR),
urine was collected over 24-h on the study day and before and
24 h after administration of tobramycin, a blood sample was
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collected to measure serum creatinine. In addition, GFR was
estimated (eGFR) as follows: (1) using the Cockcroft-Gault
formula with LBW without correction for gender for obese
and with TBW for non-obese individuals (CG-LBW) (18), (2)
using the Modification of Diet in Renal Disease (MDRD)
which was de-indexed for body surface area (BSA) by multi-
plying with individual BSA/1.73, and (3) Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) formula, al-
so de-indexed for body surface area (BSA) by multiplying with
individual BSA/1.73 (18). Equations for the different renal
function estimates are shown in the supplemental material.
Total tobramycin plasma concentrations were measured
using a commercially available, validated immunoassay kit
(Cobas® TOBR2, Roche Diagnostics GmbH, Mannheim),
with a lower limit of quantification (LLOQ) of 0.3 mg/L.
Pharmacokinetic Analysis
For each individual, AUC24 was calculated using the trape-
zoidal rule. Cmax was defined as the measured concentration
1 h after start of the 0.5-h infusion. Categorical data was
analysed using Fischer Exact test, where continuous data is
compared using the Wilcoxon Rank test.
Using all data, population pharmacokinetic modelling was
performed with NONMEM 7.3 (ICON Development
Solutions, Hanover, USA), Pearl-speaks-NONMEM (PsN)
4.6.0 and visualized using Pirana 2.9.7 (Pirana Software &
Consulting BV), R 3.4.4 and GraphPad Prism 6.0
(GraphPad So f tware , La Jo l l a , USA) ( 20–22 ) .
Concentrations below LLOQ were retained in the dataset
and analysed using the M3 method, where a likelihood for
being below LLOQ was estimated for these concentrations
(23). Discrimination between nested models was done by com-
paring the objective function value (OFV, −2 log likelihood)
as obtained from the NONMEM output. A difference in
OFV of 3.84, corresponding with a p value <0.05 for one
degree of freedom, was considered statistically significant. In
addition, goodness-of-fit plots (GOF, observed versus popula-
tion and individual predicted values, individual weighted re-
siduals versus time or population predicted values), prediction-
variability corrected visual predictive checks (pvcVPC), preci-
sion of parameter estimates, shrinkage, and individual plots
were examined for diagnostic purposes. One-, two- and three-
compartment models were evaluated as structural models.
Inter-individual variability (IIV) on the individual parameter
estimate of the ith individual (θi) was modelled according to
Eq. (1):
θi ¼ θmean  eηi ð1Þ
where θmean is the population mean parameter value, ηi is a
random variable for the ith individual with a mean of zero and
variance of ω2, assuming log-normal distribution in the
population. For residual variability a combined, proportional
and additional error model was investigated, according to eq.
(2):
Y ij ¼ Cpred;ij þ Cpred;ij  ε1
 þ ε2 ð2Þ
where Yij is the observed concentration, Cpred,ij the predicted
concentration for the jth observation in the ith individual and
ε1 and ε2 the proportional and additive errors, respectively,
with a mean of zero and variance of σ2.
Covariate Analysis
The influence of covariates was explored by plotting individ-
ual posthoc parameter estimates or the IIV estimates against
individual covariate values. Covariates were TBW, LBW (cal-
culated using the Janmahasatian formula) (19), ABW (calcu-
lated as ideal body weight (IBW) + 0.4 * (TBW-IBW) (11)),
BMI, GFR, de-indexed MDRD, de-indexed CKD-EPI,
CG-LBW, sex and age. Equations are summarized in the
supplemental material. Continuous covariates were imple-
mented using the following equations:
Pi ¼ Pp  COVCOVstandard
 X
ð3Þ
Pi ¼ Pp  1þ Z  COV−COV standardð Þð Þ ð4Þ
where Pi and Pp represent individual and population param-
eter estimates, COV represents the covariate, COVstandard
represents a population standardized (e.g. 70 kg for TBW)
or median value for the covariate, X represents the exponent
for a power function and Z represents the relative change of
the parameter in a linear covariate relationship. Linear covar-
iate relationships were tested with a slope parameter Z using
eq. (4) or by fixing the exponent X in eq. (3) to 1. In addition,
the recently described function characterising the influence of
TBW on gentamicin clearance (17), was evaluated for its per-
formance for tobramycin (i.e. equation (3) using TBW as co-
variate with an exponent of 0.729), which is an approach that
was applied before on aminoglycosides in neonates and chil-
dren (24,25). Categorical covariates were entered into the
model by calculating a separate pharmacokinetic parameter
for each category of the covariate. After entering covariates
separately into the model, their added value was statistically
tested using the OFV. In addition, if applicable, it was evalu-
ated whether the IIV for the parameter decreased upon inclu-
sion of the covariate and whether the trend in the IIV versus
covariate disappeared. In general, a forward inclusion
(p < 0.05, OFV decrease >3.8) and backward deletion
(p< 0.001, OFV decrease >10.8) strategy was employed for
inclusion of covariate. Finally, earlier mentioned general di-
agnostics were taken into account.
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Internal Model Validation
pvcVPC’s were generated using PsN (n= 1000 datasets split
for obese and non-obese) with prediction and variability cor-
rection. Bootstrap re-sampling (n= 1000, stratified on weight
group, i.e. obese and non-obese) was performed to obtain
confidence intervals for the parameters, as well as to assess
the robustness of the model.
Model-Based Simulations
Using the final PK model, Monte Carlo simulations were
performed with interindividual and residual variability in
9.993 individuals with body weights uniformly distributed be-
tween 60 and 190 kg. Values for de-indexed MDRD were
assigned to each individual using a normal distribution with
separate mean and standard deviation (SD) for obese (mean:
137 ml/min, SD: 34) and non-obese (mean: 112 ml/min, SD:
23) groups, based on the distributions found in the ongoing
AMIGO trial (Dutch Trial Registry NTR6058, n= 60 obese,
n= 32 non-obese individuals,). Four dosing scenarios were
simulated: (1) tobramycin 5 mg/kg TBW, (2) de-indexed
MDRD based dosing using the relationship between clear-
ance and MDRD as was found a-posteriori in the final PK-
model, with 75 mg*h/L as target for the AUC24 (5) and (3)
5 mg/kg ABW. For comparison, (4) simulations using a dosing
strategy based on the best function identified for TBW
(Table III) were also performed. All infusions were simulated
as single intravenous administrations given in 0.5 h.
RESULTS
Demographics and Data
A total 20 obese and 8 non-obese participants were included
in this study. Obese patients had a median TBW of 137.8 kg
(range 103–194) versus 66.3 kg (range 57–91) in the non-obese
group. Patient characteristics are shown in Table I. For each
individual, 10 samples were obtained resulting in 280
tobramycin plasma concentrations in total. Of these, 23
(8.2%) were below LLOQ of 0.3 mg/L.
The mean measured tobramycin plasma concentrations
for each timepoint are shown in Fig. 1. The AUC24 was sig-
nificantly lower in the obese group receiving tobramycin as a
single 5 mg/kg LBW dose compared to the non-obese control
group receiving a 5 mg/kg TBW dose (mean 56.1 ±
16.3 mg*h/L vs. 70.0 ± 12.0 mg*h/L, p= 0.039). Also Cmax
levels were significantly lower in the obese individuals (mean
11.8 ± 2.8 mg/L vs. 18.3 ± 2.7 mg*h/L, p< 0.001). No neph-
rotoxicity (based on the RIFLE criteria (26)) was observed in
any participant.
Pharmacokinetic Analysis
A two-compartmental model with first-order elimination from
the central compartment and a combined additional and pro-
portional residual error model best described the data. IIV
was implemented on clearance and central volume of distri-
bution. Parameters of the structural model without covariates
(base model) are shown in Table II.
Exploration using scatter plots of individual posthoc pa-
rameter estimates and IIV against different covariates indicat-
ed TBW, ABW and LBW as candidate covariates for central
volume of distribution, and de-indexed MDRD, de-indexed
CKD-EPI, CG-LBW, GFR, TBW and LBW for clearance.
Figure 2 shows the individual posthoc parameter estimate for
clearance versus the different candidate covariates, showing
particularly clear relationships for GFR, MDRD and CKD-
EPI.
For central volume of distribution, TBW in a power func-
tion, LBW and ABW as linear covariates resulted in signifi-
cant OFV drops (−25.9, −23.9 and− 29.2, respectively, all
p< 0.001). As TBW gave the best GOF (populations predict-
ed versus observed concentrations) with the least bias especially
in higher concentrations (i.e. >12 mg/L), TBW was selected
over ABW (p> 0.05). Inclusion of TBW on central volume of
distribution resulted in a reduction of IIV from 42.9% to
25.1% (Table II).
The results of the covariate implementation on CL are
shown in Table III. Table III shows that implementation
of de-indexed MDRD, de-indexed CKD-EPI, and GFR
resulted in the largest reduction in OFV, i.e. -36.3, −32.8
and − 32.3, respectively (all p < 0.001). GOF plots for all
covariates were comparable, although all models seemed
to slightly underpredict tobramycin concentrations below
10 mg/l in the non-obese individuals (data not shown).
The addition of TBW to de-indexed MDRD as covariate
for clearance improved this underprediction, however the
limited reduction in OFV (i.e. -3.4 in OFV, p > 0.05) and
only moderate improvement of GOF did not justify to
include this extra parameter. Inclusion of de-indexed
MDRD resulted in a reduction in IIV on clearance from
25.2% to 12.0% (Table II). Implementation of TBW in-
stead of de-indexed MDRD, resulted in a power function
on clearance with an estimated exponent of 0.42, and was
inferior to implementation of de-indexed MDRD (i.e.
−10.3 versus − 36.3 in OFV drop, p < 0.05, and a resulting
drop in IIV on CL of 25.2% to 20.6% versus 12.0%, re-
spectively). Implementation of the covariate relationship
between TBW and clearance as found for gentamicin in
similar study (17), i.e. a power relationship with an expo-
nent of 0.729, resulted in an even smaller drop in OFV
(i.e. -4.0, p < 0.05), with inferior GOF and only a very
modest reduction in IIV from 25.2% to 23.4%. As final
model, de-indexed MDRD was selected as covariate on
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clearance, since MDRD gave a significantly larger OFV
reduction (p < 0.05) and better GOF compared to CKD-
EPI, and since in clinical practice a serum creatinine
based eGFR such as MDRD is more readily available
than 24-h urine based GFR.
The GOF plots of the final covariate model are shown in
Fig. S1 in the supplemental material and show that the model
described the data well. The parameters of the final model
with confidence intervals based on the bootstrap analysis are
shown in Table II together with final equations for clearance
and central volume of distribution. The results from the
boostrap analysis (Table II) indicate a good precision and
stability of the final model. The prediction-variability
corrected visual predictive check (pvcVPC) shown in Fig. 3
indicates good validity of the final model, with median and
5th and 95th percentile of the observations being in concor-
dance with the 95% confidence intervals of the simulations.
Model-Based Simulations
Figure 4 shows the individual (dots), median and interquartile
range (boxplots) AUC24 values as obtained in the Monte
Carlo simulations. Quantitative results are shown in
Table S1 in the supplemental material. For individuals up to
100 kg (non-obese population), tobramycin was dosed as
5 mg/kg TBW. For obese individuals 100–190 kg,
tobramycin was dosed using the nomogram depicted in
Fig. 5, which is based on the relationship between clearance
and MDRD as found in the final covariate model. The figure
shows that when tobramycin is dosed as 5 mg/kg TBW, ex-
posure increases with increasing body weight, with higher
AUC24 values being observed in individuals with relatively
low MDRD-values (<100 ml/min, dark blue dots). Median
AUC24 per weight subgroup of non-obese individuals when
receiving 5 mg/kg TBW increases from around 50 to
80 mg*h/L with increasing body weight. For individuals
>100 kg, Fig. 4 shows that when a de-indexed MDRD-based
dosing strategy is employed (using the nomogram in Fig. 5), no
trend is visible with increasing body weight, with a median
AUC24 tightly around 75 mg*h/L. In case the 5 mg/kg
TBW dosing strategy was employed in obese individuals, an
increase in both the mean and variability (range) of exposures
is observed, with a median of around 150 mg*h/L for obese
individuals weighing around 190 kg (Fig. S2B in supplemental
material). When the MDRD-based dosing strategy is used in
non-obese individuals as well, no remaining trend in this pop-
ulation is found (<100 kg, Fig. S2A in supplemental material).
Finally, when dosing was performed based on scaled body
weight (i.e. using 0.42 as exponent for TBW (Table III)) or
ABW, no clear trends are visible in median exposure across
body weights similar toMDRD-based dosing (Fig. S2C andD
in supplemental material). However, in contrast to MDRD-
based dosing, these do yield a substantial reduction in
Table I Summary of Patient Characteristics
Morbidly obese (n=20) Non - obese (n=8) P value
Male/female 9/11 4/4 0.57
Age (years) 43.0 [27–54] 22.5 [20–25] <0.001
Total body weight (TBW, kg) 137.8 [103–194] 66.3 [57–91] <0.001
Lean body weight (LBW (19), kg) 69.3 [51–107] 49.7 [38–69] 0.0029
Body Mass Index (BMI, kg/m2) 41.9 [36–53] 22.2 [19–25] <0.001
Glomerular filtration rate based on 24-h urine collection (GFR, ml/min) 163.3 [85–230] 124.7 [98–141] 0.031
Estimated GFR
De-indexed Modification of Diet in Renal Disease (MDRD, ml/min) 127.5 [77–171] 102.6 [91–120] 0.031
De-indexed Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI, ml/min) 138.0 [78–171] 109.4 [101–129] 0.050
Cockcroft Gault with LBW (19) (obese) or TBW (non-obese) (CG-LBW, ml/min) 116.4 [69–148] 119.8 [101–138] 0.40
Tobramycin dose (mg) 340 [240–480] 320 [280–440] 0.75
Data shown as median [range] unless otherwise specified
Fig. 1 Mean± SD tobramycin plasma concentrations versus time after end
of infusion for obese (blue triangles, n=20, dose: 5 mg/kg lean body weight)
and non-obese individuals (orange squares, n=8, dose: 5 mg/kg total body
weight).
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exposures within target in individuals with increased and de-
creased renal functions, respectively (Fig. S2C and D,
Table S1).
DISCUSSION
In this report we studied the population pharmacokinetics
tobramycin across body weights from 57 to 194 kg in individ-
uals with a normal renal function. We show that with increas-
ing body weight, tobramycin clearance is best predicted using
a renal function estimate. In our data, this relationship be-
tween clearance and renal function was best described using
de-indexed MDRD, although de-indexed CKD-EPI or GFR
based on 24-h urine collection seem to lead to similar results.
In order to reach the target exposure of 75 mg*h/L in indi-
viduals of varying weights, model-based simulations (Fig. 4)
were performed showing that in obese individuals >100 kg
tobramycin should be dosed using the proposed nomogram
(shown in Fig. 5) based on the individuals de-indexedMDRD.
Strong aspects of our study design are (1) the wide range of
TBW in our study, including non-obese individuals and obese
individuals up to 194 kg, (2) the rich sampling procedure up to
24 h post-infusion and, (3) the use of a modelling and
simulation strategy that is nowadays seen as the gold standard
by regulatory authorities for approval of new dose regimens
(28).
The influence of obesity on aminoglycoside clearance has
been reported in some studies over the years (11–13,15,16,29).
Although in general these studies found an increase in clear-
ance with increasing body weight, their results have to be
interpreted with caution since individuals in most of these
studies were only moderate obese compared to present-day
standards with average body weights around 85–105 kg with
standard deviations of ±12–18 kg (12,13,16). Moreover, anal-
yses were often performed with sparse data collected up to
only 8 h (11–13,15,16). These study designs limit the ability
to properly assess drug clearance, particularly in view of the
once every 24-h dosing that is currently in practice. Only few
studies report on covariates that can be used to adequately
predict aminoglycoside clearance in obese individuals. One
clinical study by Pai et al. in 497 subjects (with 91 obese pa-
tients), report that both gentamicin and tobramycin clearance
could be best predicted using unadjusted eGFR formula
(either MDRD or CKD-EPI) rather than de-indexed eGFR
functions or the CG formula (15). Our study found better
predictions for eGFR over the CG-formula as well, although
we found that de-indexed eGFR is preferred over the
Table II Population Pharmacokinetic Parameters of the Base and Final Tobramycin Model and Results of the Bootstrap Analysis
Base model (%RSE) Final model (%RSE) Bootstrap final model (n=1000)
(95% Confidence interval)
Mean Lower Upper
Vc (L) 17.2 (7.3) –
Vc= Vc70kg * (TBW/70)
Vc 70 kg (L) – 10.6 (5.9) 10.6 8.94 12.4
CL (L/h) 6.42 (4.3) –
CL=CLMDRD 115 * (1+ Z * (MDRD-115)
CLMDRD 115 (L/min) – 6.33 (2.4) 6.33 6.02 6.63
Z – 0.00990 (3.9) 0.0100 0.0880 0.0122
Vp (L) 4.24 (15) 4.35 (5.6) 4.41 2.84 5.98
Q (L/min) 6.4 (5.1) 6.69 (1.6) 6.77 2.63 10.91
Inter-individual variability (IIV, %)
Vc 42.9 (9.3) 24.9
a (13) 24.1 14.9 30.8
CL 25.2 (14) 12.0a (13) 11.7 7.90 14.5
Residual variability
Proportional error 0.112 (12) 0.116 (11) 0.115 0.0880 0.141
Additive error (mg/L) 0.369 (13) 0.346 (11) 0.342 0.239 0.445
OFV 351.7 289.6 276.6 185.9 367.2
aη-shrinkage in the final model is 8% for IIV on CL and 6% for IIV on Vc. CL Clearance from the central compartment, CLMDRD 115 Clearance from the central
compartment for a person with a MDRD of 115 ml/min,MDRDDe-indexed Modification of Diet in Renal Disease (in ml/min), OFVObjective Function Value, Q
intercompartmental clearance between VC and VP, RSE Relative standard error, TBW Total body weight in kg, Vc Central volume of distribution, Vc70 kg Central
volume of distribution for a 70 kg person
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unadjusted estimates. A possible explanation for this differ-
ence might be that Pai et al. had to rely on sparse data, poten-
tially making it more difficult to estimate individual
tobramycin clearances. In addition, the authors used
Mosteller’s equation for estimating BSA instead of the
Dubois and Dubois formula as employed in our analysis,
which may result in some differences. However, our results
did not change significantly when the Mosteller’s equation
was employed (data not shown). Lim et al. found in a retro-
spective study with 342 patients with ~30% being obese, that
Fig. 2 Individual posthoc clearance values for tobramycin (n=28, in L/h) versus (a) total body weight (TBW), (b) 24-h urine glomerular filtration rate (GFR), (c)
eGFR based on de-indexed Modification of Diet in Renal Disease (MDRD), (d) de-indexed Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and
(e) Cockcroft-Gault using LBW in obese and TBW in non-obese (CG-LBW). Obese individuals are shown in blue triangles, non-obese individuals in orange
squares.
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de-indexed eGFR outperformed their unadjusted counter-
parts in predicting aminoglycoside clearance (29). Leader et al.
reported that ABW used in the CG equation is the best pre-
dictor for gentamicin clearance. Since this is an older study, no
information is available on the performance of the eGFR for-
mulas (12). Some other papers looked directly into predicting
GFR in the obese population. These studies might be of
relevance for our study, since in healthy adults, tobramycin
clearance is shown to be primarily mediated through glomer-
ular filtration (30). These papers generally agree that GFR can
be best predicted using the de-indexed form of MDRD or
CKD-EPI (31,32), or the CG formula with LBW or ABW
(18,33,34). These conclusions are in line with our results, but
should be translated to tobramycin clearance with caution
Fig. 3 Prediction- and variability-corrected visual predictive checks (pvcVPC) of the final model for non-obese (upper left panel) and obese (upper right panel)
individuals (n=1000 simulations). The observed concentrations are shown as black circles, with median, 2.5th and 97.5th percentiles of the observed data as
solid line, lower dashed line and upper dashed line, respectively. The grey shaded areas depict the 95% confidence intervals of the median (dark grey) and 2.5th
and 97.5th percentiles (light grey) of predicted concentrations. Lower panels show the observed proportion below LLOQ (black dots), where shaded areas
depict the 95% confidence interval of these proportion based on the simulated concentrations.
Table III Impact of Different Covariates on Tobramycin Clearance (CL)
Model Parameter relationship (subpopulation) X (exponential) / Z (linear) Number of parameters OFV ΔOFVa
TBW on Vc – – 8 325.8 (reference)
TBW on CL Exponential (all) 0.42 9 315.6 −10.3
TBW on CLb Exponential (all) 0.729 FIX 9 321.8 −3.96
MDRD on CL Linear (all) 0.0099 9 289.6 −36.2
CKD-EPI on CL Linear (all) 0.0089 9 293.0 −32.8
GFR on CL Linear (all) 0.0055 9 293.5 −32.3
CG-LBW on CL Linear (obese) 0.0069 9 315.9 −9.88
aOFV drop relative to reference model (base model with TBW on Vc)
b Covariate relationship for clearance and TBW as reported for gentamicin in similar study (17)
CG-LBW Cockcroft Gault using lean body weight for obese and total body weight for non-obese individuals, CKD-EPI De-indexed chronic Kidney Disease
Epidemiology Collaboration, CL Clearance, GFR Glomerular Filtration Rate based on 24-h urine collection, OFV Objective Function Value, MDRD De-indexed
modification of Diet in Renal Disease, TBW Total body weight, Vc central volume of distribution
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since other (active) processes might be involved besides glo-
merular filtration when using GFR to predict clearance of a
drug. In summary, it appears that most literature point to a
renal function estimate to be most predictive for tobramycin
clearance in obese individuals, although results from previous
studies are conflicting as to how these renal function estimates
should be corrected in obese individuals. The current study,
with rich data collected in a wide range of body weights and
(unimpaired) renal functions, in our opinion now definitively
shows that de-indexedMDRDorCKD-EPI outperform body
weight, the CG formula (using either TBW or LBW) and
unadjusted renal function estimates in predicting tobramycin
clearance in obese individuals.
Our results on tobramycin differ from results that we have
found for gentamicin in a recently performed prospective
pharmacokinetic study that studied a similar patient popula-
tion in a similar study design (17). This study showed that the
increase in gentamicin clearance was best described by TBW
with an estimated allometric exponent of 0.73. In contrast to
tobramycin, renal function estimates (eGFR or GFR based on
24-h urine collection) were inferior to TBW in predicting gen-
tamicin clearance, despite the fact that in both studies individ-
uals with a similar distribution in body weights and renal
function (all >60 ml/min) were included. Interestingly, this
finding has been reported before by other studies, describing
Fig. 4 Monte Carlo simulations (n=9.993) for individuals <100 kg receiving one IV dose of 5 mg/kg total body weight (TBW) tobramycin, and individuals
>100 kg received a MDRD-based tobramycin dose using the nomogram in Fig. 5. Each dot represents the AUC24 (in mg*h/L) of one individual in the dataset,
where the color shows the de-indexed MDRD in ml/min (calculated as MDRD * body surface area (BSA)/1.73) of this individual (ranging from dark blue to dark
red with increasing MDRD). The boxplots represent median and interquartile range of AUC24 values within a specific total body weight subgroup. The grey
dashed line shows the target AUC24 of 75 mg*h/L, black dashed lines show the 80–125% range (EMA acceptance criteria for bio-equivalence studies (27))
relative to this target value. AUC Area under the curve, MDRD Modification of Diet in Renal Disease TBW Total body weight.
Fig. 5 Dosing nomogram for tobramycin dose (in mg) based on the final
tobramycin population PK model in non-obese and obese patients with body
weights ranging from 57 to 194 kg and de-indexed MDRD values (calculated
as MDRD * body surface area (BSA)/1.73) ranging from 77 to 171 ml/min,
aiming for an AUC24 of 75 mg*h/L. The recommended tobramycin dose is
calculated using equation: Dose (mg) = AUC24, target × 6.33 × (1 +
0.0099 × (MDRD− 115)). where AUC24,target represents the target
AUC24 in mg*h/L of 75 and MDRD represents the de-indexed MDRD in
ml/min. Since the PK data consists of MDRD values from 77 to 171 ml/min,
dose recommendations extrapolation to values outside these should be
interpreted with caution (grey area in the nomogram). MDRD Modification
of Diet in Renal Disease.
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stronger correlations between eGFR and drug clearance for
tobramycin than gentamicin (15,29). To explain this differ-
ence between tobramycin and gentamicin, it could be hypoth-
esized that transporters play a role. For gentamicin an in-
crease in renal organic cation transporter 2 (OCT2) activity
and consequently enhanced renal uptake has been reported
that may contribute to increased gentamicin clearance in the
obese. In an obese overfed mouse model, OCT2 activity in-
creased with obesity, leading to increased renal accumulation
of gentamicin (35). In addition, it is well established from stud-
ies with metformin, which is a well-known OCT2 substrate,
that for OCT2 substrates drug clearance is influenced by al-
tered OCT2 function. A human study showed that OCT2
genotypes associated with impaired activity led to a reduced
apparent metformin clearance (CL/F) (36). Moreover, an in-
crease in metformin CL/F was seen in obese adolescents com-
pared to non-obese children, possibly due to an increase in
renal OCT2-activity (37). In this light, the contrasting results
on gentamicin and tobramycin clearance might be explained
by a relatively higher dependence of gentamicin on OCT2-
mediated renal uptake in favor of glomerular filtration.
Although to our best knowledge, this never has been properly
studied, this hypothesis is further substantiated by the obser-
vation that tobramycin accumulates less in the kidney com-
pared to gentamicin and therefore might be less nephrotoxic
(38). Further (preclinical) research seems warranted to clarify
these differences between tobramycin and gentamicin PK
based on the current study results.
An important question is what the target AUC24 is when
treating patients with tobramycin. An AUC24 of 75 mg*h/L
for pathogens with a MIC of 0,25–1 mg/L has been shown to
be have the best balance between effectiveness and toxicity for
aminoglycosides (5). Therefore, we provided a nomogram
that can be used to determine the initial tobramycin dose for
obese individuals based on the patient’s de-indexed MDRD
targeting an AUC24 of 75 mg*h/L (Fig. 5). When this dose
strategy is employed in the obese, a stable median AUC24 up
to 190 kg without trends can be expected. In addition, outer
ranges lie around ~75% to ~125% relative to the target of
75 mg*h/L (absolute 95% confidence interval of 57.4–93.5
and 56.9–92.8 mg * h/L for non-obese and obese individuals,
respectively, visualized in Fig. 4). This is acceptable, consider-
ing the acceptance range of 80–125% as specified by the
EuropeanMedicines Agency (EMA) for bio-equivalence stud-
ies (27). In contrast, when a 5 mg/kg TBW dose regimen is
employed in obese individuals, the 95% confidence intervals
lie between 22.2 mg*h/L and 184.1 mg*h/L, corresponding
to 30% to 246% relative to the target AUC24. This high
variability, which is most pronounced for the highest body
weights of the obese population, can be explained by the fact
that renal function is not taken into account in this strategy.
Moreover, median AUC24 steadily increases with increasing
body weight. In current daily practice, tobramycin is mostly
dosed using ABW as is recommended by several papers, in
order to maximize peak levels in obese individuals (11,39,40).
However, like with TBW-based dosing, this approach does
not consider variation in renal function. As such, our simula-
tions show that this approach leads to a substantial reduction
in the proportion of patients having an AUC within the target
AUC24 compared to using the dose nomogram for the obese
population (43.9% versus 93.6%). Therefore, even though in-
adequate target concentrations can be picked up by therapeu-
tic drug monitoring that is usually performed after a one or
more dosages, we do not recommend to use TBW or ABW-
based dose regimens in obese individuals.
A few remarks should be made regarding the proposed
nomogram. First, the dose nomogram shows dose recommen-
dations for de-indexed MDRD values ranging from 30 to
250 ml/min. However, our PK-model is based on a dataset
with MDRD values of 77 to 171 ml/min. Dose recommenda-
tions outside of this MDRD-range should therefore be
interpreted with caution in clinical practice. Second, the
AUC-target of 75 mg*h/L used in the nomogram is based
on an AUC/MIC ratio of 75, with a corresponding MIC
≤1 mg/L, as has been proposed earlier (5). However, it is
known that the wild-type population of most gram-negatives
extends to 2 mg/L (8). Therefore, higher dosages might be
necessary to cover the whole range of pathogens with MIC
values up to 2 mg/L. Third, our study was specifically de-
signed to obtain dose recommendations for obese individuals.
A mg/kg-based dosing is already a widely accepted strategy
for non-obese individuals. The proposed nomogram is expect-
ed to lead to an adequate exposure in the non-obese popula-
tion as well (as shown in Fig. S3B in the supplemental
material). Despite this, our simulations of a 5 mg/kg TBW
dose (Fig. 4) show that in non-obese individuals, this strategy
generally results in considerable variability. Last, after deter-
mining the initial tobramycin dose, we recommend that sub-
sequent dosages should always be individualized by therapeu-
tic drug monitoring, preferably with a limited sampling strat-
egy in combination with model informed precision dosing
based on Bayesian PK-software that is capable of translating
the measured tobramycin concentrations to an individualized
dose prediction (41).
Several limitations may apply to our study. First, we only
included relatively healthy obese and non-obese individuals
with an estimated renal function >60 ml/min/1.73 m2.
Therefore, extrapolation of our study results to critically-ill
patients with or without renal impairment should be done
with caution, since critical illness can have an additional im-
pact on PK. Secondly, obese study participants underwent
bariatric surgery during the PK study, which might influence
the PK results. However, since these surgeries in our hospital
are very short (<1 h), and performed laparoscopically with
minimal blood loss (<50 mL), we expect this impact to be
negligible.
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CONCLUSION
In conclusion, we found that in non-obese and obese patients
up to 194 kg, tobramycin clearance shows an important rela-
tion with renal function estimates. In obese individuals, de-
indexed MDRD was superior over TBW in predicting
tobramycin clearance. In order to yield similar exposure
across body weights, we therefore propose that the
tobramycin dose in individuals >100 kg should be based on
de-indexed MDRD. To aid the clinician in finding the opti-
mal dose, we provide a dose nomogram that can be used to
determine the correct initial tobramycin dose by integrating
MDRD and target AUC.
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